UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date of
Report (date of earliest event reported): September 3, 2008
Commission
File No. 0-11178
UTAH
MEDICAL PRODUCTS,
INC.
(Exact
name of Registrant as specified in its charter)
|
UTAH
|
87-0342734
|
|
(State
or other jurisdiction of incorporation or organization)
|
(I.R.S.
Employer Identification No.)
|
7043
South 300 West
Midvale,
Utah 84047
Address
of principal executive offices
|
Registrant's
telephone number:
|
(801)
566-1200
|
|
ITEM
7.01 Regulation FD Disclosure
Update of
Projected Minimum Royalties Expected in 2009 and 2010
In UTMD’s
SEC Form 10-K for the year ended December 31, 2007, the Company made the
following statement regarding its expectations for receiving royalties in future
years:
“As a
matter of policy, UTMD licenses its proprietary technology to others in
circumstances where licensing does not directly compete with UTMD's own
marketing initiatives. During 2007, the Company received $450 in
royalty income, the same as in 2006 and 2005. Based on the expiration
dates of the patents for which the current royalty income is being received and
the $450 annual maximum, UTMD expects royalties of at least $450, $450 and $310
in 2008, 2009 and 2010, respectively. UTMD’s future financial
performance also depends on the marketing ability of other companies that
license UTMD’s technology.”
The
projection for 2008 was accurate. Based on a new interpretation of
the expiration dates of patents for which current royalty income is being
received, the Company does not expect to receive the minimum royalties in 2009
and 2010 as previously announced.
Pursuant
to the requirements of the Securities Exchanges Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
|
UTAH MEDICAL PRODUCTS,
INC.
|
|
|
REGISTRANT
|
|
|
|
|
|
|
|
|
|
Date:
9/3/2008
|
By:
|
/s/
Kevin L. Cornwell
|
|
|
|
Kevin
L. Cornwell
|
|
|
|
CEO
|